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Background: proMMP-9 binds to CLL cells through the hemopexin domain (PEX9), contributing to disease progression.
Results: A 20-residue sequence (P6) within PEX9 inhibits CD44-mediated CLL-proMMP-9 interaction and cell migration. P6
cooperates with the previously identified sequence P3, also located in PEX9.
Conclusion: P6 is a CD44-binding site and impairs proMMP-9 effects on CLL.
Significance: P6 may be a novel therapeutic target in CLL.
(pro)MMP-9 binds to CLL cells through the PEX9 domain and
contributes toCLLprogression.Tobiochemically characterize this
interaction and identify potential therapeutic targets, we prepared
GST-PEX9 forms containing structural blades B1B2 or B3B4.We
recentlydescribedasequence inbladeB4(P3sequence) thatbound
41 integrin and partially impaired cell adhesion andmigration.
Wehave now studied the possible contribution of theB1B2 region
to cell interaction with PEX9. CLL cells bound to GST-B1B2 and
CD44 was the primary receptor. GST-B1B2 inhibited CLL cell
migration as effectively as GST-B3B4. Overlapping synthetic pep-
tides spanning the B1B2 region identified the sequence FDA-
IAEIGNQLYLFKDGKYW,present inB1 and contained inpeptide
P6, as themost effective site. P6 inhibited cell adhesion to PEX9 in
a dose-dependentmanner andwith an IC50 value of 90M. P6 also
inhibitedcell adhesiontohyaluronanbuthadnoeffectonadhesion
toVCAM-1 (41 integrin ligand), confirming its specific interac-
tionwithCD44.Spatial localizationanalysesmappedP6tothecen-
tral cavity of PEX9, in close proximity to the previously identified
P3 sequence. Both P6 and P3 equally impaired cell adhesion to
(pro)MMP-9. Moreover, P6 synergistically cooperated with P3,
resulting in complete inhibition of CLL cell binding to PEX9, che-
motaxis, and transendothelial migration. Thus, P6 is a novel
sequence in PEX9 involved in cell-PEX9/(pro)MMP-9 binding by
interactingwithCD44.Targetingbothsites,P6andP3, shouldeffi-
ciently prevent (pro)MMP-9binding toCLLcells and its patholog-
ical consequences.
Chronic lymphocytic leukemia (CLL)4 consists of the accu-
mulation in peripheral blood of CD5 B lymphocytes that infil-
trate the bone marrow and secondary lymphoid tissues (1, 2).
CLL cells differ from normal B cells in many genetic and func-
tional aspects, including overexpression of pro/mature matrix
metalloproteinase-9 (pro)MMP-9, a member of the MMP
protein family (3–5). Indeed, elevated intracellular levels of
(pro)MMP-9 correlate with advanced CLL stage and poor
patient survival (6). Moreover, and although a mostly secreted
MMP (7), we have shown that (pro)MMP-9 is consistently
present at the CLL cell surface, due to the binding to a docking
complex formed by 41 integrin and a 190-kDa CD44 variant
(8). (pro)MMP-9 binding to this complex results in in vitro and
in vivo cell arrest and induction of a cell survival pathway con-
sisting in Lyn/STAT3 activation and Mcl-1 up-regulation
(8–10). The latter effect did not involve the MMP-9 catalytic
activity but required the hemopexin domain (PEX9), as a
recombinant mutant lacking PEX9 did not bind to cells (8).
Although this survival pathway was mainly triggered by 41
(9), CD44 can also up-regulate Mcl-1 and promote CLL cell
survival upon interaction with its ligand hyaluronan (11, 12).
Accordingly, Zhang et al. (13) recently used a humanized anti-
CD44 monoclonal antibody and identified this molecule as a
target in CLL.
These previous reports indicate that (pro)MMP-9 localiza-
tion at the cell surface contributes toCLLpathology bymultiple
mechanisms and that targeting PEX9-cell interaction may rep-
resent a therapeutic advantage. PEX9 consists of four-bladed
-propeller structure (blades 1–4) (14), and Dufour et al. (15)
applied a genetic approach in fibrosarcoma and carcinoma cells
to identify two sequences in the outermost -strand of blade 1
(SRPQGPFL) and blade 4 (NQVDQVGY), which affected
* Thisworkwas supportedbyGrantSAF2012-31613andby theRedTemáticade
Investigación Cooperativa en Cáncer (RD12/0036/0061) (to A. G. P.) from the
Ministry of Economy and Competitivity (Madrid, Spain); S2010/BMD-2314 (to
A. G. P.) fromtheComunidaddeMadrid/EuropeanUnion; andbyagrant from
the Fundación Puerta deHierro (Madrid, Spain) (to J. A. G.-M.).
1 Supported by a fellowship from theMinistry of Economy and Competitivity.
2 Supported by the Junta de Ampliación de Estudios program, Consejo Supe-
rior de Investigaciones Científicas/European Union, Spain.
3 To whom correspondence should be addressed: Centro de Investigaciones
Biológicas, Consejo Superior de Investigaciones Científicas, Ramiro de
Maeztu9, 28040Madrid, Spain. Tel.: 34-91-837-3112 (ext. 4430); Fax: 34-91-
536-0432; E-mail: agarciapardo@cib.csic.es.
4 The abbreviations used are: CLL, chronic lymphocytic leukemia; HUVEC,
human umbilical vein endothelial cell(s); Ab, antibody; VCAM-1, vascular
cell adhesion molecule-1; BCECF-AM, 2,7-bis(carboxyethyl)-5(6)-car-
boxyfluorescein-acetoxymethyl ester.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 22, pp. 15340–15349, May 30, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
15340 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 22•MAY 30, 2014
 at CSIC - Centro de Investigaciones Biológicas on A
ugust 28, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(pro)MMP-9-CD44 interaction and (pro)MMP-9 dimerization
and migration, respectively. Additionally, two small-molecule
compounds targeting PEX9 inhibited carcinoma growth and
metastasis (16).
We recently reported that isolated PEX9 also bound to CLL
cells and induced intracellular signaling (17). Using recombi-
nant truncated forms of PEX9,we found the following: 1) blades
3–4 (B3B4 region) supported cell adhesion via41 integrin; 2)
a synthetic peptide (named P3) containing the sequence
PGVPLDTHDVFQYREKAYFC, present in blade 4, inhibited
(pro)MMP-9-induced cell adhesion, transendothelial migra-
tion, and intracellular signaling; and 3) the P3 sequence specif-
ically interfered with 41 (pro)MMP-9 interaction (17). The
P3 effect was clearly significant but partial, suggesting the exist-
ence of additional cell-binding sites outside the B3B4 region.
In the present report, we have addressed this possibility and
show that blades 1–2mediate cell adhesion primarily involving
CD44. We have identified a novel sequence within blade 1 that
inhibits CLL cell binding to PEX9 and (pro)MMP-9 as well as
cell migration. Moreover, this sequence cooperates with the
previously identified 41-binding P3 sequence in blade 4.
Targeting both sites may thus constitute an efficient therapeu-
tic approach to prevent (pro)MMP-9 binding to CLL cells and
subsequent pathological consequences.
EXPERIMENTAL PROCEDURES
Patients andCells—Approval was obtained from theConsejo
Superior de Investigaciones Científicas Bioethics Review Board
for these studies. Peripheral blood samples from 15 CLL
patients representing different disease stages and prognostic
markers (Table 1) were obtained after receiving informed con-
sent. None of the patients had received treatment at the time of
this study. B-lymphocytes were purified by Ficoll-Hypaque
(Nycomed, Oslo, Norway) centrifugation and (if needed) nega-
tive selection with anti-CD3-conjugated Dynabeads (Invitro-
gen). The resulting B cell population was 92% CD19 and
72%CD5, determined on aCoulter EpicsXL flow cytometer
(Beckman Coulter, Fullerton, CA). Human umbilical vein
endothelial cells (HUVEC) were purchased from Lonza and
cultured as reported (4, 8).
Antibodies, Reagents, Proteins, and Peptides—mAbs HP2/1
(anti-4 integrin subunit, function-blocking), HP1/7 (anti-4
integrin subunit, non-blocking), and HP2/9 (anti-CD44, func-
tion blocking) were obtained from Dr. Francisco Sánchez-Ma-
drid (Hospital de la Princesa, Madrid, Spain). Rabbit polyclonal
antibodies to glutathione S-transferase (GST, sc-459) and
MMP-9 (sc-6841-R) were from Santa Cruz Biotechnology
(Santa Cruz, CA). HRP-labeled Abs to rabbit or mouse IgG
were fromDako (Glostrup, Denmark). Alexa Fluor 488-labeled
Ab was from Molecular Probes (Eugene, OR). Hyaluronan was
fromSigma-Aldrich(catalogno.63357).Vascularcell adhesionmol-
ecule-1 (VCAM-1), CXCL12, and TNF- were from R&D Sys-
tems (Minneapolis, MN). (pro)MMP-9 was isolated from
THP-1 cell cultures as described (18) or purchased from Calbi-
ochem (Darmstadt, Germany). GST fusion proteins corre-
sponding to the entire PEX9 domain (GST-PEX9), or truncated
forms lacking blades 3–4 (GST-B1B2) or blades 1–2 (GST-
B3B4) (Fig. 1A) were prepared exactly as described (16). PEX9-
derived peptides (Table 2) were synthesized on an automated
multiple peptide synthesizer (AMS 422, ABIMED Analysen-
Technik GmbH, Langenfeld, Germany). Spatial localization of
peptides within PEX9 was determined using the Chimera Pro-
gram (version 1.5.3, Resource Biocomputing Visualization and
Informatics, University of California at San Francisco, San
Francisco, CA).
Cell Adhesion and Soluble Binding Assays—Adhesion assays
were performed on 96-well plates coated with 0.5% BSA or
various concentrations of appropriate proteins. Except when
indicated, GST-PEX9 concentrations of 0.2 and 0.4 M were
chosen for adhesion and soluble binding assays, respectively.
2  105 CLL cells were incubated with 1.4 ng/ml 2,7-bis-
(carboxyethyl)-5(6)-carboxyfluorescein-acetoxymethyl
ester (BCECF-AM,Molecular Probes) for 20min, suspended in
RPMI 1640/0.5% BSA (adhesion medium) and added to the
coated wells. After 60 min at 37 °C, attached cells were lysed
with PBS/0.1% SDS and quantified using a fluorescence ana-
lyzer (BMG Labtechnologies, Offenburg, Germany). For inhi-
bition experiments, cells were incubated (30 min, 37 °C) with
appropriate Abs (10 g/ml) or peptides (500 g/ml, 197–270
M) prior to adding to the wells. For binding assays in solution,
1  105 cells were incubated in 100 l adhesion medium (for
constitutive (pro)MMP-9 expression) or medium containing
the various proteins or peptides for 30 min at room tempera-
TABLE 1
Clinical characteristics of CLL patients
F, female; M, male.
Patient
Sex/Age
(years) Stagea
4
(%) CD38/ZAP70b Ig statusb
1 M/69 C/IV 74 / ND
2 M/70 B/II 75 / Unmutated
3 M/79 B/II 43 / Unmutated
4 M/68 B/II 12 /ND ND
5 M/59 C/IV 30 / Unmutated
6 M/64 A/I 35 /ND Mutated
7 M/48 B/I 10 / ND
8 F/54 A/0 93 /ND Unmutated
9 M/68 ND 36 /ND ND
10 ND ND 99 /ND ND
11 F/70 C/IV 80 /ND ND
12 M/66 B/II 91 / ND
13 M/63 B/II 61 /ND ND
14 F/69 C/IV 99 /ND ND
15 M/62 ND 90 /ND ND
a Clinical CLL staging was determined according to established classifications
(1–2).
b Elevated expression of CD38, ZAP70, and an unmutated Ig status are considered
bad prognostic markers (1–2). 4 integrin subunit expression was also deter-
mined for each sample and is indicated as the percentage of positive cells. ND,
not determined.
TABLE 2
Synthetic peptides prepared in this study
Numbers in parentheses indicate the position within proMMP-9 of the amino acid
residues contained in each peptide.
Blades B3B4-derived peptide
P3 (654–674) PGVPLDTHDVFQYREKAYFC
Blades B1B2-derived peptides
P6 (521–541) FDAIAEIGNQLYLFKDGKYW
P7 (539–559) KYWRFSEGRGSRPQGPFLIA
P8 (556–576) LIADKWPALPRKLDSVFEER
P9 (574–590) EERLSKKLFFFSGRQVWVYT
P10 (588–608) VYTGASVLGPRRLDKLGLGA
Reversed P6 peptide
P6rv WYKGDKFLYLQNGIEAIADF
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ture. After washing with ice-coldmedium, cells were incubated
with anti-MMP-9 rabbit polyclonal antibodies or control Abs
(30 min, 4 °C), washed with cold PBS, and incubated (30 min,
4 °C) with Alexa Fluor 488-labeled secondary Abs. Surface-
bound proteins were analyzed by flow cytometry. To calculate
IC50 values, cells were incubated with increasing concentra-
tions of peptides (average range, 2–270 M), prior to the adhe-
sion or soluble binding assays. Values were determined using
the SigmaPlot program (Systat Software, Inc., San José, CA).
For cooperativity analyses between P6 and P3 peptides, CLL
cells were incubated with a given concentration of one peptide
(20 M) and increasing concentrations of the other peptide (30
min, 37 °C) prior to the adhesion or soluble binding assays. To
determine whether the combination of both peptides was syn-
ergistic or additive the CompuSyn software (BioSoft, Cam-
bridge, UK) was used. This program allows the calculation of
the combination index based on the algorithm of Chou and
Talalay (19). Combination index values1 indicate synergism,
whereas values 1 indicate an additive effect.
Cell Migration Assays—For chemotaxis assays, 5 105 CLL
cells with or without previous incubation with the appropriate
proteins or peptides were added to Transwell Filters (Costar,
New York, NY) and allowed to migrate toward medium alone
or containing 150 ng/ml CXCL12 in the lower chamber. After
24 h at 37 °C, transmigrated cells were counted by flow cytom-
etry. For transendothelial migration, 0.75  105 HUVEC were
plated on fibronectin-coated (10 g/ml) Transwell filters and
expression of VCAM-1 (41 integrin ligand, involved in tran-
sendothelial migration) on confluent monolayers was stimu-
lated with 15 ng/ml TNF-, for 16 h prior to the assay. 5 105
CLL cells, with or without previous incubation with the appro-
priate proteins or peptides, were added to the HUVEC mono-
layer, and, after 24 h,migrationwas quantitated as explained. In
both types of assays, migrated cells were expressed as the per-
centage of the total number of cells added, also counted by flow
cytometry.
Statistical Analyses—Statistical significance of the data were
determinedwith a repeatedmeasures analysis of variance using
General Linear Model procedures of SAS 9.3 (SAS Institute,
CaryNC). A p value of 0.05 was considered significant.Mean
pairwise comparisons were computed with the two-tailed
Student’s t test (  0.05) with the GraphPad InStat software
(version 3.05, GraphPad Software, San Diego, CA). All values
are expressed as means	 S.D.
RESULTS
Blades 1–2 in PEX9 Constitute a Novel Cell Adhesion-medi-
ating Region and Primarily Interact with CD44 in CLL Cells—
We recently reported that blades 3–4 of PEX9 (B3B4, Fig. 1A)
supports CLL cell adhesion via 41 integrin and that the P3
sequence, contained in blade 4 (see Table 2), partially inhibits
cell interactionwith PEX9 and (pro)MMP-9 (17). To determine
whether additional sites outside B3B4 were also involved in cell
adhesion, we prepared GST fusion proteins containing either
the entire PEX9domain (GST-PEX9) or deletions of blades 3–4
(GST-B1B2, proMMP-9 residues 508–613) or blades 1–2
(GST-B3B4, proMMP-9 residues 609–707) (Fig. 1, A and B)
and tested them in cell adhesion assays. Fig. 1C shows that, in
agreement with our previous results (17), GST-PEX9mediated
cell adhesion in a dose-dependent manner, reaching 76% aver-
FIGURE 1. CLL cells bind to immobilized GST-B1B2 primarily via CD44. A, schematic drawing of the proMMP-9 structure and the GST-fusion proteins
corresponding to the hemopexin domain (PEX9) prepared in this study. The four structural blades of PEX9 (B1–B4) are indicated. B, Western blot analysis of the
purified GST-PEX9 constructs after Coomassie Blue staining. C, BCECF-AM-labeled CLL cells (six different samples) were added to wells coated with increasing
concentrations of the indicated proteins. After 60 min at 37 °C, attached cells were quantitated using a fluorescence analyzer. D, BCECF-AM-labeled CLL cells
(three samples), with orwithout previous incubationwith the indicatedAbs, were added towells coatedwith 0.2MGST-B1B2 or GST-B3B4, and adhesionwas
quantitated as explained. All values represent the percentage of the total number of cells added. *, p 0.05; **, p 0.01; ***, p 0.001.
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age adhesion at the maximal concentration tested. Interest-
ingly, GST-B3B4 and GST-B1B2 alsomediated cell adhesion in
a dose-dependent manner, with similar maximum values for
both proteins (average 63 and 57% for GST-B3B4 and GST-
B1B2, respectively). Thus, although the maximum % of cell
attachment attained by these forms was lower than for the
parental GST-PEX9 (p  0.05 for GST-B3B4 and p  0.01 for
GST-B1B2), likely due to their truncated nature, GST-B1B2
was as efficient as GST-B3B4 in promoting cell adhesion. Cells
did not attach to GST alone at any of the concentrations tested
(Fig. 1C).
To identify the receptor recognizing GST-B1B2, we tested the
effect of blocking 41 integrin or CD44 (both (pro)MMP-9
receptors (8)) function with antibodies on cell adhesion to this
substrate. Cell preincubation with the function-blocking
anti-4mAbHP2/1 had amild effect (19% inhibition), whereas
the anti-CD44mAbHP2/9 was highly effective, reducing adhe-
sion by 68% (Fig. 1D). The control HP1/7 antibody had no
effect. This was clearly opposite to the inhibition pattern
observed for adhesion to GST-B3B4 (Fig. 1D), where blocking
CD44 had a minor effect (20% inhibition), and 41 was the
primary receptor as we reported previously (17).
The PEX9 B1B2 Region Inhibits CLL Cell Chemotaxis and
Transendothelial Migration—Constitutive (pro)MMP-9 is
important for CLL cell migration and invasion (4, 6), and we
previously showed that PEX9 or its B3B4 region inhibit this
migration (17).We now studiedwhether the B1B2 PEX9 region
modulated CLL cell chemotaxis and transendothelial migra-
tion. Cells from three different samples were incubatedwith 0.4
M GST, GST-B1B2, or, for comparison, GST-B3B4 and GST-
PEX9, and their migratory ability analyzed after 24 h using
Transwell chambers. In chemotaxis assays, the average value
for control cell migration in response to CXCL12 was 12%, and
this was normalized to 100. Cell preincubation with GST had
no effect (data not shown), but preincubation with GST-B1B2
inhibited chemotaxis by 72% and thus was as effective as the
positive inhibitory controls GST-B3B4 (70% inhibition) or
GST-PEX9 (77% inhibition) (Fig. 2A). The effect of GST-B1B2
was also analyzed in transendothelial migration assays. In these
experiments, 18% control cells migrated in response to
CXCL12, and this was normalized to 100. GST-B1B2 also sig-
nificantly inhibited this migration by 62%, again comparable
with the effect of GST-B3B4 (66%) or GST-PEX9 (69%) (Fig.
2B). Altogether, these results indicated that B1B2 was a func-
tional regionwith the ability tomodulate CLL cell adhesion and
migration.
Identification of Functional Amino Acid Sequences within the
PEX9 B1B2 Region—To identify the specific cell-binding
sequence(s) within PEX9 blades 1–2, we prepared five overlap-
ping synthetic peptides (P6–P10) spanning residues 521–608
of proMMP-9 (Table 2 and Fig. 3A) and tested their ability to
block cell adhesion to GST-PEX9 (0.2 M). In these initial
experiments, peptides were used at 500 g/ml, equivalent to
209M (P6 andP8), 212M (P7), 198M (P9), and 244M (P10)
concentrations, all in a similar molar range. In the absence of
peptides, 44% of cells (average, n  8 different samples)
attached to GST-PEX9, and this was normalized to 100. Fig. 3B
shows that peptide P6, representing the FDAIAEIGNQLYLFK-
DGKYW sequence located in blade 1, was the most effective,
impairing cell adhesion to GST-PEX9 by 59%. The adjacent
peptide P7, containing a sequence (SRPQGPFL) shown previ-
ously to be involved in CD44 interactions in carcinoma cells
(14), also inhibited adhesion although to a lesser extent (42%
inhibition). Peptides P8, P9, and P10 did not significantly affect
cell adhesion.
We next analyzed whether these peptides also affected cell
binding of soluble GST-PEX9. CLL cells from four different
patients were treated with peptides P6–P10 at the mentioned
M concentration, followed by incubation with GST-PEX9 and
analysis by flow cytometry. Fig. 3C shows for a representative
sample that, as observed for cell adhesion, P6 was the most
effective peptide, impairing binding of soluble GST-PEX9 to
CLL cells by 62%, whereas P7 diminished adhesion by 44%
(average of seven different samples). Peptides P8, P9, and P10
had no effect.
Having identified P6 and P7 as the most effective inhibitory
sequences in PEX9 blades 1–2, we further compared the effect
of both peptides by performing dose-dependent inhibition
analyses. After initial tests, the chosen coating concentration
for GST-PEX9 in these experiments was 0.1M. 41% of control
CLL cells attached to this concentration, and this was normal-
ized to 100. The previously identified P3 peptide located in
FIGURE 2. Effect ofGST-PEX9, GST-B1B2, andGST-B3B4onCLL cellmigration.CLL cells (five patients) treated or notwith the indicated proteins for 30min,
were added to the upper chamber of uncoated (A) or TNF--activated HUVEC-coated (B) Transwell filters. 150 ng/ml CXCL12 was added to the medium in to
the bottom chamber, and migrated cells were counted after 24 h by flow cytometry. Average values represent the percentage of the total number of cells
added. **, p 0.01.
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blade 4 (17) was also included in these assays for comparison.
Additionally, and as a control for specificity, we prepared a
peptide containing the reverse sequence present in P6 (peptide
P6rv, Table 2). Fig. 3D shows that both P6 and P7, but not the
control peptide P6rv, inhibited cell adhesion to GST-PEX9 in a
dose-dependentmanner, with average IC50 values of 90M (P6)
and 280 M (P7), thus confirming the above results on the dif-
ferent activity of both peptides. The IC50 for P3 in these ana-
lyses was 35M. The reverse peptide P6rv did not inhibit adhe-
sion at any concentration, confirming the specificity of the
FIGURE 3. Identification of active sequences within the B1B2 region in PEX9. A, ribbon diagram of the monomeric PEX9 domain showing the location in
blades 1–2 of the synthetic peptides P6-P10 prepared in this study (see Table 2). B, BCECF-AM-labeled CLL cells (eight samples), with or without previous
incubation with the indicated peptides (500 g/ml), were added to wells coated with 0.2 M GST-PEX9. After 60 min, cell adhesion was quantitated as
explained.C, CLL cells, treated or not for 30minwith the indicated peptides (500g/ml), were incubatedwith soluble GST-PEX9 (0.4M). After 30min, binding
was analyzed by flow cytometry using an anti-MMP-9 antibody. A representative experiment is shown.White areas, constitutive (pro)MMP-9 expression; dark
gray areas, (pro)MMP-9 expression upon GST-PEX9 binding. Average quantitative values of the seven samples studied are also shown. D, BCECF-AM-labeled
CLL cells were incubated (30 min, 37 °C) with the indicated concentrations (conc.) of P3, P6, P7, or P6rv peptides and added to wells coated with 0.1 M
GST-PEX9. After 60min at 37 °C, attached cells were quantitated using a fluorescence analyzer. Adhesion values in the absence of peptideswere normalized to
100. E, three of the CLL samples tested in Dwere treated for 30 min with the indicated peptide concentrations and incubated with 0.2 M soluble GST-PEX9.
After 30min, bindingwas analyzedby flow cytometry using an anti-MMP-9 antibody. Binding in the absence of peptideswas normalized to 100. IC50 values for
all peptides tested were calculated using the SigmaPlot program. **, p 0.01; ***, p 0.001.
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sequences tested. Peptide inhibition of soluble GST-PEX9 cell
binding was also dose-dependent, rendering IC50 values of 75,
220, and 40 M, respectively, for P6, P7, and P3 (Fig. 3E). Alto-
gether, these results established that peptides P6 and P7 were
functional sequences in PEX9 blade 1 and that P6 was more
effective than P7 in inhibiting CLL cell interaction with PEX9.
The P6 Sequence Interferes with CD44-Ligand Interaction—
The results shown in Fig. 1D indicated that the B1B2 region
primarily interacted with CD44.We therefore studied whether
the twomost active peptides from this region, P6 and P7, inter-
feredwith CD44-ligand binding. CLL cells, preincubated or not
with P6 (209M), P7 (212M), or the control peptide P6rv (209
M), were tested for adhesion to the natural CD44 ligand hya-
luronan. 48% of control cells attached to hyaluronan, and this
was normalized to 100. As observed for B1B2 in Fig. 1D, cell
preincubation with P6 significantly reduced cell adhesion to
hyaluronan by 58%, whereas preincubation with P7 produced a
minor effect (25% inhibition), and P6rv did not inhibit adhesion
(Fig. 4A). In contrast to this P6 activity, the P3 peptide (blade 4,
Table 2), shown previously to impair 41 function (17), was a
poor inhibitor of cell adhesion to hyaluronan (18% inhibition,
Fig. 4A). Peptides P6, P7, and P3, displayed similar activities for
inhibition of cell adhesion to proMMP-9 (42–48% inhibition),
whereas the control P6rv peptide had no effect (Fig. 4B). To
further establish the specificity of these peptides in interfering
with (pro)MMP-9 cell binding, we studied their effect on CLL
cell adhesion to VCAM-1, a well known ligand for 41 integ-
rin. Fig. 4C shows that none of these peptides affected cell adhe-
sion to VCAM-1, confirming the specificity of their effect on
CLL cell interaction with (pro)MMP-9.
Cooperative Effect of Peptides P6 and P3 in Inhibiting CLL
Cell Adhesion and Migration—We next studied whether the
newly identified active site P6, present in blade 1, cooperated
with the previously described P3 sequence located in blade 4, in
inhibiting cell adhesion and migration. For comparison, the P7
peptide alone or combined with P3 was also included in these
experiments. In initial experiments, CLL cells were preincu-
bated with or without P3 (198 M), P6 (209 M), or both pep-
tides together and tested for adhesion to GST-PEX9. Peptide
P6rv (209 M) alone or combined with P3 or P6 was also
included as control in these experiments. Fig. 5A shows that P3
and P6 inhibited adhesion to this substrate by 65 and 66%,
respectively, confirming our previous results. Importantly,
the combination of both peptides significantly increased this
inhibition to 81%, thus reducing adhesion to the basal levels
induced by the control GST (13%) and indicating a cooper-
ative effect between both sites. In contrast, combining P7
with P3 did not increase the individual effect of either pep-
tide, confirming that only the P6 sequence specifically coop-
erated with P3. Additionally, combinations of these peptides
with the control P6rv did not modify the effect of P6, P7, or
P3 alone, further confirming the specificity of the P6-P3
combination.
A cooperative effect between P6 and P3 was also observed
when analyzing soluble GST-PEX9 binding to CLL cells. In this
case, the combination of P6 and P3 increased the inhibitory
effect of P6 (70%) or P3 (76%) to 85%, again reducing binding to
the basal levels attained by GST (13%) (Fig. 5B). All other pep-
tide combinations had no effect (Fig. 5B).
Having established the specific cooperation of the P6 and P3
sequences in inhibiting cell adhesion, we next determined
whether this cooperation was synergistic or additive. To this
purpose,wemeasured the effect of increasing concentrations of
one peptide (P3 or P6) in the absence or presence of a low
concentration (20 M) of the other peptide. Fig. 5, C and D,
shows that the combination of P6 andP3 significantly increased
the inhibitory effect of the individual peptides at all concentra-
tions tested. The calculated combination index in these assays
was1 in both cases and for all concentrations tested (Fig. 5,C
and D), indicating that the cooperation of peptides P6 and P3
was synergistic.
We next tested the effect of these peptides, alone or com-
bined, on CLL cell migration. Preincubation of CLL cells (five
different samples) with P6 or P3 reduced CXCL12-induced cell
chemotaxis (average control, 12%; normalized to 100) by 48 and
54%, respectively, and the combination of both peptides
reduced migration to basal levels in the absence of chemokine
(Fig. 6A). Likewise, P6 and P3 impaired CLL transendothelial
migration (average control, 16%; normalized to 100) by 55 and
66%, respectively, and the combination of both peptides com-
pletely inhibited chemokine-induced cell migration (Fig. 6B).
Combinations of P6 or P3 with the control P6rv did not increase
the inhibition attainedbyP6orP3 alone (Fig. 6,A andB). In agree-
ment with the observed P3-P6 cooperation, spatial localization
FIGURE4.Effectof syntheticpeptidesonCLLcell adhesion tohyaluronan,proMMP-9, andVCAM-1.BCECF-AM-labeledCLL cells,withorwithoutprevious
incubationwith the indicated peptides, were added towells coatedwith 4Mhyaluronan (A), 60 nM proMMP-9 (B), or 18 nM VCAM-1 (C), and cell adhesionwas
analyzed as explained. Values are the averageof threedifferent experimentswith triplicate determinations andwere obtained after normalizing control values
to 100. *, p 0.05; **, p 0.01; ***, p 0.001.
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analyses indicated that these two sequences were located in close
proximity within the PEX9 central pocket (Fig. 6C).
DISCUSSION
We have studied whether the B1B2 region (blades 1–2) of
PEX9 had a functional role in (pro)MMP-9 interaction with
CLL cells. Ourmajor findings are as follows: 1) the B1B2 region
mediates cell adhesion by interacting primarily with CD44; 2)
B1B2 is a good inhibitor of CLL cell migration; 3) the most
active sequence in B1B2 is FDAIAEIGNQLYLFKDGKYW,
located in blade 1 and represented by the synthetic peptide P6;
and 4) P6 synergistically cooperates with the previously
described sequence P3 (FPGVPLDTHDVFQYREKAYFC,
blade 4) to increase inhibition of cell adhesion andmigration.
The GST-B1B2 fusion protein studied here effectively medi-
ated CLL cell adhesion and inhibited cell migration. This
FIGURE 5. Cooperative effect of the P6 and P3 peptides on inhibition of CLL cell binding to GST-PEX9. A, BCECF-AM-labeled CLL cells (five different
patients), with or without previous incubation with the indicated peptides (500 g/ml), were added to wells coated with 0.1 M GST-PEX9. After 60 min, cell
adhesion was quantitated as explained. B, CLL cells, treated or not for 30min with the indicated peptides (500g/ml), were incubated with soluble GST-PEX9
(0.2M). After 30min, bindingwas analyzedby flow cytometry using an anti-MMP-9 antibody. Quantitative values represent the average of three different CLL
samples. BCECF-AM-labeled CLL cells were incubated for 30 min with mixtures of 20M P6 and increasing concentration of P3 (C) or 20M P3 and increasing
concentrations of P6 (D), and added to wells coated with 0.1M GST-PEX9. After 60min, cell adhesion was quantified as explained. Combination index values
for both experiments were calculated using the CompuSyn software. Graphs in C and D represent the means and 95% confidence intervals of three different
experiments, each with a different CLL sample and triplicate determinations. *, p 0.05; **, p 0.01.
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behavior was similar to the previously described functions for
the GST-B3B4 protein, containing blades 3–4 of PEX9 (17).
However, there were major differences regarding the receptors
involved in the recognition of both proteins. Although we pre-
viously identified 41 integrin as the main receptor for the
B3B4 region (17), our present results clearly indicate that cell
interactionwith theB1B2 region primarily involvedCD44. This
is in agreement with the known role for CD44 as a docking
receptor for (pro)MMP-9 in many cell systems and with its
ability to bind to the PEX9 domain (7, 8, 20, 21). Moreover,
blade 1 was shown to be required for CD44 binding to PEX9 in
transfectedCOS-1 cells (15) and for binding to the PEXdomain
of MT1-MMP (MMP-14) in several carcinoma cell lines (22),
also in line with the CD44 recognition of the B1B2 region
reported here. In our previous report (17), the HP2/9 anti-
CD44 antibody did not impair cell adhesion to GST-PEX9 and
silencingCD44 had a limited effect (19% inhibition). Therefore,
one possible explanation for our current results on the activity
of GST-B1B2/CD44 interaction is that the site recognized by
CD44 in B1B2 may be totally or partially cryptic within the
immobilized PEX9 domain. An alternative explanation is that
the interaction of PEX9 with 41 integrin (via binding to
B3B4) is of higher affinity than the interaction with CD44, thus
prevailing in adhesion to the entire PEX9 domain. In support of
this, soluble GST-B3B4 was able to bind to CLL cells while
soluble GST-B1B2 only bound poorly (17).
Using a series of overlapping peptides we have identified the
FDAIAEIGNQLYLFKDGKYW sequence in blade 1 as a novel
CD44 binding site in PEX9. The synthetic peptide P6 contain-
ing this sequence effectively inhibited CLL cell interaction with
PEX9, as well as chemotaxis and transendothelial migration.
This suggests that P6 and the HP2/9 antibody may bind to dif-
ferent sites in CD44 and thus affect its properties differentially.
Importantly, P6 also inhibitedCLL cell adhesion to hyaluronan,
the natural ligand for CD44, further confirming that the P6
sequence bound toCD44 and blocked its subsequent functions.
In a previous report (15), Dufour et al. identified a different site
in PEX9, SRPQGPFL, located in the outermost -strand of
blade 1, that when presented as a synthetic peptide inhibited
(pro)MMP-9-CD44 interaction and COS-1 and carcinoma cell
migration. In our present study, this sequence was contained in
peptide P7 (KYWRFSEGRGSRPQGPFLIA) and also inhibited
CLL cell interaction with PEX9. However, there were several
differences between the P6 and P7 peptides: 1) the inhibitory
effect of P7 was weaker than the effect of P6, with IC50 values of
280 and 90 M, respectively; 2) P7 was a poor inhibitor of cell
adhesion to hyaluronan. Thus, our results do not contradict the
report by Dufour et al. (15) but reveals a new sequence within
blade 1, which is more active in CLL cells than SRPQGPFL.
Because peptide P6 was not tested in the study of Dufour et al.
(15), it is not known if the P6 sequence is also active in other cell
systems.
Besides displaying different inhibitory activity, peptides P6
and P7 also differ in their spatial location within blade 1 of
PEX9. Although P7 localizes in the outermost -strand, P6 is
located within the central cavity (Figs. 3A and 5E). The central
localization of P6 is similar to that of peptide P3 (PGVPLDTH-
DVFQYREKAYFC), which we reported previously to bind to
41 integrin and impair 41-MMP-9-induced functions in
CLL cells (17). Interestingly, two recent studies have identified
FIGURE 6.Cooperative effect of the P6 andP3peptides on inhibitionof CLL cellmigration.CLL cells, treated or notwith the indicated peptides for 30min,
were added to the upper chamber of Transwell filters uncoated (A) or coatedwith TNF--activated HUVEC (B). 150 ng/ml CXCL12was added to themedium in
to the bottom chamber, and migrated cells were counted after 24 h by flow cytometry. Average values represent the percentage of the total number of cells
added. *, p 0.05; **, p 0.01. C, ribbon diagram of themonomeric PEX9 domain showing the spatial location of the P6 and P3 amino acid sequences within
blades 1 and 4 of PEX9, respectively.
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small molecules that bind to PEX9 or to the PEX domain of
MMP-14 and inhibit carcinoma cell migration, proliferation,
and tumor growth (16, 23). The binding site of these com-
poundswasmapped by in silico approaches to the central cavity
in PEX9, further supporting that this is the main cell-binding
region in the PEX domain and thus constitutes a target. More-
over, and in agreement with the spatial proximity of P6 and P3,
our study shows that P6 synergistically cooperated with P3,
resulting in significantly increased inhibition of cell adhesion
and migration. The fact that a similar cooperation between P7
and P3was not observed, further supports that the P6 sequence
is the most active site in blade 1 and specifically coordinates
with P3 to ensure a stronger effect.
Our present report therefore establishes that PEX9 binding
to CLL cells involves the cooperative interaction of the P6
sequence (blade 1) with CD44 and the P3 sequence (blade 4)
with 41 integrin. Numerous studies have addressed the role
of 41 in CLL and revealed its importance in CLL aggressive-
ness, in vitro and in vivomigration, cell survival, and drug resis-
tance (9, 24–29). Indeed, some of these functions are induced
by 41 upon binding to (pro)MMP-9/PEX9 (9). The role of
CD44 in CLL has been less studied, but we previously showed
that blocking CD44 interaction with (pro)MMP-9 prevented
the (pro)MMP-9-induced survival effect in CLL cells (9). Addi-
tionally, several reports have shown that CD44 interaction with
hyaluronan (30–32) or (pro)MMP-9 (15) regulates CLLmigra-
tion. CD44-hyaluronan interaction and subsequent signaling
also protected CLL cells from spontaneous and drug-induced
apoptosis (11, 12) and contributed to disease progression in a
CLL murine model (12). Moreover, a recent study has shown
that a mAb specific for CD44 was cytotoxic for CLL cells and
reverted the engraftment of leukemia cells in murine models
(13), highlighting the role of CD44 as a therapeutic target in
CLL. As both 41 integrin and CD44 are receptors for
(pro)MMP-9/PEX9 (8) and contribute to CLL pathology, tar-
geting the identified PEX9 sequences that bind to these recep-
tors should constitute a good therapeutic approach to prevent
CLL progression.
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